Bone protective effects of TNFα inhibition in rheumatoid arthritis are thought to be mediated by inhibiting synovial osteoclast differentiation and activity. However, it has not been addressed, if TNFα inhibitors alter the pool of peripheral osteoclast precursor cells (OPCs). Here, we blocked TNFα function in C57BL/6 mice with antigen induced arthritis (AIA) using the soluble TNFα receptor etanercept. Synovial bone lesions and osteoclasts were markedly reduced upon Etanercept in the early chronic phase of AIA. Unexpectedly this was not associated with a reduced recruitment of circulating OPCs to the arthritic joint nor to reduced synovial inflammation. In contrast we found that OPC numbers in bone marrow and blood were significantly reduced. Overall our study suggests that arrest of osteoclast mediated bone lesions upon inhibition of TNFα is, at least initially, based on reduced OPC availability in the periphery, and not on OPC recruitment or local anti-inflammatory effects in the arthritic joint.
Introduction
Inflammation-induced bone lesions are a key feature in human rheumatoid arthritis (RA) and animal models of chronic arthritis [1, 2] . The differentiation of new bone resorbing osteoclasts in the arthritic joint critically depends on two essential factors: Macrophage colony stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL) [3, 4] . An additional requirement for synovial osteoclastogenesis is the availability of OPCs, which belong to the monocyte/macrophage lineage [5] . Monocytes are divided into two subsets, classical and non-classical monocytes, which in mice, can be distinguished by their Ly6C high CX3CR1 inter and Ly6C low CX3CR1 high marker expression, respectively [6] . After maturation in the bone marrow, classical and non-classical monocytes circulate in blood and become inflammatory macrophages upon recruitment to the site of inflammation. These infiltrating monocyte-derived macrophages are potent producers of pro-inflammatory cytokines and efficiently initiate immune responses [7, 8] . In contrast, tissue resident macrophages are considered to be more important for the maintenance and restoration of tissue integrity. Due to selfproliferation, they maintain themselves mostly independently of newly recruited hematopoietic cells [9, 10] . In RA, inflamed joints provide an optimal environment for the differentiation of bone resorbing osteoclasts [11] . On one side, M-CSF and RANKL expression is induced by the high level of pro-inflammatory cytokines [12, 13] ; on the other side, continuous infiltration of circulating monocytes into the inflamed synovial compartment provides a cell pool that is prone to differentiate into osteoclasts. The bone protective effect mediated by blockade of TNFα is well known and mostly explained by attenuation of inflammatory processes, favoring osteoclastogenesis within the arthritic joint [14, 15, 16] . However, there is emerging evidence, that anti-TNFα therapy affects osteoclastogenesis outside of the synovial compartment. TNFα has been associated with alterations in the pool of peripheral OPCs [17] . Furthermore, patients that were treated with TNFα inhibitors showed a bone protective effect that was not dependent on the inflammation in the arthritic joint [18] . Although myeloid markers were previously used to characterize OPC populations, the precise distinction between different monocyte subsets was often not completely taken into consideration [17, 19] .
In the present study, we used heterozygous CX3CR1-GFP knock-in mice and attributed an osteoclastogenic potential to the classical Ly6C-high CX3CR1
inter monocyte subset. We demonstrate that in an AIA mouse model TNFα inhibition reduced availability of these OPCs in bone marrow and blood without affecting their recruitment to the still highly inflamed joint.
Materials and methods

Animals and experimental arthritis model
C57BL/6J mice were obtained from Janvier (Genest Saint Isle, France). CX3CR1-GFP knock-in mice (Cx3cr1 /J) mice were obtained from Jackson Laboratory (Bar Harbor, Maine, USA). All mouse lines were backcrossed to C57BL/6J background for at least eight generations. Mice were housed in individually ventilated cages under specific pathogen-free conditions with water and food ad libitum. Animal procedures were performed in accordance with the Swiss legislation on the protection of animals and were approved under the application number BE 18/12 and BE 55/15 by the veterinary office of the Canton of Bern.
AIA was induced in 6-8 weeks old female mice using a previously described protocol [20] . Briefly, mice were immunized by subcutaneous injection of 100 μg methylated bovine serum albumin (mBSA) (Sigma) in complete Freund's adjuvant (CFA) on day-21 and in incomplete Freund's adjuvant (IFA) (Santa Cruz Biotechnology, Inc) on day-14. CFA was additionally supplemented with 4 mg/ml heat-killed Mycobacterium tuberculosis strain H37RA (Becton, Dickinson and Company). In parallel to each immunization, 200 ng of Bordetella pertussis toxin (List biological laboratories, Inc., Campbell, CA, USA) was administrated by an intraperitoneal injection. Arthritis was induced by injecting 100 μg of mBSA in 20 μl physiologic saline into the knee joint, whereas injection of saline was used as sham control for the contralateral knee. 10 mg/kg of etanercept (Enbrel®, Pfizer) or human polyclonal IgG (BioXCell) was subcutaneously injected every other day after arthritis induction.
Adoptive transfer of monocytes
Monocytes were isolated from bone marrow and enriched by using CD115 MicroBead kit (MACS, miltenyibiotec). Cells were labeled with CSFE (Thermofisher, 1:1000 dilution) at 37°C for 20 min. 5 × 10 6 cells were injected via the femoral artery into AIA WT mice on day 14. After 30-60 min, periarticular tissue was harvested and recruitment of CD45 high CD11b + CSFE + monocytes was quantified by flow cytometry.
Flow cytometry of bone marrow, blood and periarticular cells
200 μg bromodeoxyuridine (BrdU) was intravenously injected and mice were euthanized after 30 min. Using flow cytometry, local cell proliferation was analyzed by BrdU incorporation in cells from femora and periarticular tissues. Cell surface staining was performed for 1 h at 4°C. For additional intracellular BrdU staining, cells were incubated in Cytofix/Cytoperm Buffer (BDBioscience). Cells were kept in 10% DMSO at −80°C. After thawing, cells were refixed and treated with 300 μg/ ml DNAse for 1 h at 37°C and stained for BrdU. Total blood count was determined with a scil VetABC™ Hematology Analyzer (Scil animal care company, Viernheim, Germany). Total cell count of bone marrow and periarticular tissue was determined by using PKH26 reference microbeads (Sigma). Samples were measured with the LSR II (BDBioscience) and data were analyzed with the FlowJo software.
Monocyte sorting and in vitro osteoclast cultures
Bone marrow cells were harvested from CX3CR1-GFP knock-in mice and stained with anti-CD117 antibody. Non-classical monocytes were defined as CX3CR1-GFP high CD117 − and classical monocytes as CX3CR1-GFP inter CD117 − . For sorting from blood, nonclassical and classical monocytes were defined by their CX3CR1-GFP high and CX3CR1-GFP inter expression, respectively, and blood from mice with on-going arthritis from AIA day 3 was used. Sorting was performed by using ARIA flow cytometry (BDBioscience). 30`000 cells were distributed in a 48-well plate and cultured in complete α-MEM medium supplemented with 30 ng/ml M-CSF and 50 ng/ml RANKL at 37°C. After 5 days for bone marrow and after 14 days for blood cultures, cells were fixed, stained for TRAP (Sigma) and the number of multinucleated TRAP + osteoclasts/ well was determined.
Histology, immunohistochemistry and microCT
Mice were perfused with 4% PFA and knee joints were harvested. After overnight post-fixation, knees were decalcified in 15% EDTA and paraffin embedded. One section of each knee was sagittally cut through the center of the joint and stained with H&E and for TRAP, respectively. Synovial inflammation on H&E stained knee sections were scored as followed: perivascular leukocyte infiltration (0-5), synovial leukocyte infiltration (0-5), synovial hyperplasia (0-5). Bone parameters on H&E knee sections were scored by bone erosion severity on meniscus (0-4) and tibial joint surface (0-4). Synovial osteoclasts on TRAP stained knee sections was scored by TRAP + osteoclasts located on the meniscus (0-3) and tibial bone surface (0-3). For immunohistochemistry, knee sections were incubated for 1 h with primary rat and secondary rabbit anti-rat antibody. A system-HRP labeled polymer anti-rabbit (Envision Dako) was added for 30 min on paraffin sections. Sections were washed and incubated in the substrate solution with AEC tablets. F4/80 and Gr-1 staining was scored by intensity (0-5) in the complete synovial compartment and the bone surface area. Undecalcified tibia from CX3CR1-GFP knock-in mice were sectioned by using the CryoJane Tape-Transfer System (Leica) according to Jiang et al. [21] . MicroCT analysis was done 14 days after arthritis onset in IgG (n = 4) and etanercept (n = 4) treated mice.
Serum chemokines in non-arthritic and arthritic mice with and without etanercept treatment
Circulating chemokines from non-arthritic as well as arthritic mice with and without anti-TNF treatment with etanercept were measured in serum 14 days after onset of arthritis. For this purpose a membrane -based antibody array/sandwich immunoassay from R&D Systems (Bio -Techne AG, Zug, Switzerland) was used to detect 25 chemokines in mouse serum samples.
Antibodies for flow cytometry
All rat anti-mouse monoclonal antibodies used for flow cytometry were purchased from BioLegend: anti-Ly6G (18A), anti-CD45 (30-F11), anti-CD115 (AFS98), anti-CD117 (2B8), anti-CD11b (M1/70), anti-Ly6C (HK1.4), anti-BrdU (Bu20a), anti-NK1.1 (PK136), anti-B220 (RA3-6B2), anti-CD19 (6D5), anti-SiglecF (E50-2440), anti-CD90.2 (30-H12), IgG1, κ (RTK2071), IgG2a, κ (RTK2758), IgG2b, κ (RTK4530). Negative controls were done with unspecific isotype antibodies.
Antibodies for histology
Rat anti-mouse F4/80 (clone CI:A3-1, produced in house). Rat antimouse Gr-1 (NIMP-R14, Abcam). Rat IgG2b, κ (RTK4530, BioLegend).
Statistical analyses
Statistical analysis was performed using GraphPad Prism 6.0 software (Graphpad software, La Jolla, CA, USA). Data were compared by MannWhitney test. Asterisks indicate significant differences (*P b 0.05, **P b 0.01 and***P b 0.001, ****P b 0.0001).
Results
Antigen-induced arthritis leads to recruitment of monocytic osteoclast precursors and osteoclastogenesis in inflamed knees
In order to investigate if TNFα affects synovial osteoclastogenesis on the level of osteoclast precursors, we chose AIA as an animal model in which synovial inflammation and bone destruction is associated with continuous recruitment of circulating leukocytes/osteoclast precursors. The antigen injection into the knee cavity of mice that were previously two times immunized with adjuvants-antigen solutions, led to a marked increase in synovial cellularity as determined by histology of the knee joint already at day 3 post knee-injection. In the early chronic phase of AIA, 14 days after knee-injection, synovial histopathology was additionally associated with pannus formation and alterations in joint architecture (Fig. 1A) . Analysis by flow cytometry of periarticular tissue revealed two different CD45 + leukocyte populations in knee joints of sham-treated and AIA mice. While non-inflamed knee joints of shamtreated mice only harbored tissue resident CD45 inter cells, periarticular tissues of arthritic knees showed infiltration of CD45 high leukocytes (Fig. 1B, left) . The total number of these infiltrating CD45 high leukocytes increased in arthritic knees from AIA day 3 to 14 ( Fig. 1B, right) . As a next step, we investigated whether infiltration of CD45 high leukocytes was associated with the appearance of new bone resorbing osteoclasts. In contrast to the osteoclast-free synovium of uninflamed sham knees and arthritic knees from day 3, TRAP + osteoclasts were found adjacent to tibial bone lesions in the early chronic phase on day 14 of AIA ( Fig.  1C) . We hypothesized that the presence of synovial monocytes/macrophages was prerequisite for the observed osteoclastogenesis in the arthritic joint on day 14. We defined synovial monocyte/macrophages as CD45 high CD11b + Lineage neg cells since it has been shown that the recruitment of monocytic osteoclast precursors from the blood to the knee joint rapidly induces expression of complex marker sets related to tissue macrophage differentiation [8] . By using the gating strategy shown in the FACS plots in Fig. 1D (left), the amount of synovial monocytes/macrophages was quantified in the acute and early chronic phase of AIA. Indeed, increased infiltration of these osteoclast precursor cells correlated with the appearance of synovial osteoclasts and structural damage in the knee joint on day 14 of AIA ( Fig. 1D, right) .
Classical monocytes rather than non-classical monocytes exhibit osteoclastogenic properties
We observed in the early chronic phase of AIA, 14 days after arthritis induction, osteoclast-mediated bone resorption, which was associated with infiltration of monocytes/macrophages. This suggested that recruitment of monocytic osteoclast precursors substantially contributed to these new synovial bone lesions. To investigate which monocyte subsets hold the potential to differentiate into osteoclasts, we took advantage of CX3CR1-GFP knock-in mice, in which CX3CR1 promoter activity drives expression of GFP and thus allows distinction of classical and non-classical monocytes. We confirmed that classical CX3CR1-GFPinter and non-classical CX3CR1-GFP high bone marrow monocytes expressed monocytic markers such as CD11b and CD115 (Supplementary Fig. 1A ). Bone marrow cells were isolated and classical CX3CR1-GFP inter and non-classical CX3CR1-GFP high monocytes that were negative for the bone marrow precursor marker c-kit/CD117, were sorted by flow cytometry (Fig. 2A) . After 4-6 days of culture under proosteoclastogenic conditions in the presence of M-CSF and RANKL, TRAP + osteoclasts were counted. While mixed bone marrow cells and classical CX3CR1-GFP inter monocytes gave rise to osteoclasts, non-classical CX3CR1-GFP high monocytes failed to develop into osteoclasts ( Fig. 2B and C). Bone marrow contains in addition to monocytes also macrophages and dendritic cells, which may as well express CX3CR1. In contrast, CX3CR1-GFP expression in monocytes of the blood was over 90% associated with monocytic markers (Supplementary Fig. 1B ). We therefore used blood from AIA mice for isolating and sorting monocytes to avoid any contaminations by differentiated macrophages. Consistent with bone marrow cells, only classical, but not non-classical blood monocytes differentiated into osteoclasts in vitro (Fig. 2D) (Fig. 2E ).
Anti-TNFα therapy reduces bone lesions and the number of synovial osteoclasts
To elucidate the precise role of TNFα on bone resorbing osteoclasts and their precursor cells, we confirmed as a proof of concept that TNFα contributed to AIA pathogenesis. Arthritis was induced in TNFR1/2 −/− C57BL/6 mice, lacking both receptors for TNFα. Indeed, TNFR1/2 −/− C57BL/6 mice showed significantly ameliorated arthritis in terms of synovial inflammation and reduced numbers of TRAP + osteoclasts in the knee joint on day 14 of AIA (Supplementary Fig. 2A and B) .
To have a clinically more relevant experimental setup, AIA was induced in WT C57BL/6 mice, which were from then on treated every second day with 10 mg/kg TNFα antagonist, the soluble TNFα receptor etanercept.
Inhibition of TNFα had a bone protective effect, which was reflected by fewer pathological bone lesions (Fig. 3A) and a reduced number of synovial TRAP + osteoclasts in the knee joint on day 14 of AIA ( Fig. 3B ).
However, despite the reduced synovial osteoclastogenesis, etanercept treated mice still showed highly inflamed knee joints that were infiltrated with leukocytes (Fig. 3C) . Fig. 3A and B) . Furthermore, neither bone marrow nor blood showed any difference in leukocyte and monocyte numbers between control and etanercept treated mice on AIA day 3. Only the number of neutrophils was slightly reduced in the blood of anti-TNFα treated animals on day 3 ( Supplementary Fig.  4A and B) . In contrast to day 3, etanercept treatment resulted in clear cellular changes in the synovial compartment in the early chronic phase on day 14 of AIA. Although anti-TNFα therapy did not result in any significant difference in the availability of F4/80 + macrophages (Fig. 4A (Fig. 4B) . It has been reported that tissue resident cells often show increased proliferation rates upon inflammation and thereby substantially contribute with infiltrating cells to the increased amount of synovial cells [9] . We therefore examined if alterations in local cell proliferation contributed to the different knee cellularity observed on day 14 4D , left). The recruitment of adoptively transferred CSFE + monocytes into the arthritic knee was not different between etanercept and control treated animals supporting the notion that etanercept does not directly influence monocyte recruitment into the inflamed joint (Fig. 4D, right) .
Anti-TNFα therapy leads to fewer circulating and proliferating monocytic osteoclast precursors in blood and bone marrow, respectively
Since neither synovial inflammation nor monocyte recruitment from blood to synovial tissue was affected by anti-TNFα therapy, we were wondering if changes in peripheral OPC populations led to fewer osteoclasts in the inflamed joint of etanercept treated mice. We therefore analyzed the cellular composition of bone marrow and blood by flow cytometry. Indeed, in bone marrow, etanercept treated mice showed despite unchanged numbers of total CD45 + leukocytes, fewer Ly6G + neutrophils and more importantly, fewer proliferating BrdU + monocyte precursors ( Fig. 5A and B) . This was accompanied by a dramatic reduction of the numbers of circulating monocytes. Etanercept treated mice harbored fewer circulating classical Ly6C high monocytes and Ly6G + neutrophils, while the total number of circulating CD45 + leukocytes remained unchanged (Fig. 5C ). These data nicely correlated with the decreased number of Gr-1 + myeloid cells and osteoclasts found in synovial tissue of etanercept treated animals.
3.6. Anti-TNFα therapy does not regulate circulating chemokine levels in arthritic and non-arthritic mice 14 days after onset of arthritis we checked for serum levels of 25 different chemokines (CCL11/eotaxin, CCL12/MCP-5, CCL2/JE/MCP-1, CCL21/6 Ckine, CCL22/MDC, CCL27/CTACK, CCL28, CCL3/CCL4 (MIP1alpha/MIP-1beta), CCL5/RANTES, CCL6/C10, CCL8/MCP-2, CCL9/MIP-1 gamma, Chemerin, Complement Component C%/C5a, CX3CL1/ Fractalkine, CXCL1/KC, CXCL10/IP-10/CRG-2, CXCL11/I-TAC, CXCL12/ SDF-1, CXCL13/BLC/BCA-1, CXCL16, CXCL2/MIP-2, CXCL9/MIG, IL-16, LIX). Serum levels of mice in the following experimental settings were checked: non-arthritic controls (n = 4), non-arthritic but etanercepttreated (n = 4), arthritic (n = 4), arthritic and etanercept-treated (n = 4). However, we found no statistically significant differences of circulating chemokine levels. The data are shown in a Supplementary Fig. 5 .
Discussion
In the present study we asked to which degree anti-TNFα therapy reduces osteoclast mediated bone resorption by affecting osteoclast precursor cells. We examined if availability of OPCs in bone marrow, blood and synovia and their recruitment to the arthritic knee was reduced upon blockade of TNFα. As a first step, we aimed to characterize the mouse osteoclast precursor populations, which belong to the monocyte/macrophage lineage. OPCs were previously defined by using general monocytic markers, however, the distinction between the two known classical and non-classical monocyte subpopulations, Ly6C-high CX3CR inter respectively, was rarely applied [17, 19] . Interestingly, there is increasing evidence that, not only in terms of osteoclastogenic potential, these monocyte subsets play key roles for different aspects in RA pathogenesis [8, 22, 23] . Sorting CX3CR1 inter and CX3CR1 high monocytes by flow cytometry from bone marrow and blood showed that the osteoclastogenic potential was restricted to classical monocytes, which is also supported by findings in humans [24] . We also found a difference in the maturation and the number of osteoclasts between the culture from bone marrow and blood. We can only speculate that one probable explanation might be the higher number of macrophages and of Ly6high cells in bone marrow compared to blood that are able to proliferate [25, 26] . Moreover, bone marrow contains the more complex composition of proliferating progenitor cells and matured macrophages [27] . This is also reflected by the non-homogeneous cell population in bone marrow compared to the homogeneous cell population in blood as shown in Supplementary Fig. 1 . Classical monocytes are known for their efficient recruitment to the site of infection [6]. Thus we hypothesized that infiltration of circulating monocytes into the arthritic knee is key for newly formed bone lesions by giving rise to bone resorbing osteoclasts in the arthritic joint. In accordance with this, it has been shown in parabiosis experiments that circulating GFP + monocytes from CX3CR1-GFP knock-in mice differentiated into mature GFP + osteoclasts in bone tissue of WT mice [28] . However, we also detected over the course of AIA low numbers of proliferating tissue resident CD45 inter macrophages in inflamed and non-inflamed knees. We cannot fully exclude that these tissue resident macrophages might also give rise to osteoclasts in our model. However, tissue resident macrophages are known for their specific tissue-related tasks and their mature phenotype, which argues against their plasticity as OPCs [9, 10] . Having defined the monocytic OPC population, we were wondering if the observed bone protective effect upon anti-TNFα therapy can be attributed to reduced recruitment of circulating monocytes to the inflamed knee. TNFα and other inflammatory cytokines are key effector molecules regulating leukocyte migration as they efficiently upregulate endothelial cell adhesion molecules at the site of inflammation [29] . Surprisingly, the recruitment of adoptively transferred monocytes into the inflamed knee was not different between control and etanercept treated mice, which might be explained by the still strong on-going inflammation in the knee at this timepoint of arthritis in our model. In accordance with this, the number of infiltrated CD45 high leukocytes and the synovial inflammation in knees of etanercept treated mice were not reduced on day 14 post knee-injection. Similar to RA patients, who showed bone protection irrespective of the clinical response (pain and joint swelling), to anti-TNF therapy [18, 30] , we found lower numbers of osteoclasts and bone lesions in still inflamed joints. In contrast, by MicroCT analyses we saw no differences in cortical and trabecular volumes and densities in knees from AIA control and etanercept treated mice. One explanation could be that the time point of 14 days after induction of AIA was too early for morphometric bone analysis to detect significant differences in AIA with and without anti-TNF treatment. However, our data demonstrate that TNFα inhibition affects synovial osteoclastogenesis beyond the synovial compartment in the arthritic joint. Indeed, we showed that TNFα inhibition critically reduced the pool of proliferating bone marrow monocytic OPCs. This observation is in line with other studies, which reported that absence of TNFα reduced the number of immature myeloid cells in the bone marrow [31] . Even more impressive was the marked reduction of circulating classical monocytes in the blood of etanercept treated mice on day 14 after arthritis onset. One possible explanation for their lower number in blood would be cell death. However, infliximab treated RA patients did not show any signs of apoptosis in peripheral blood monocytes [32] . More likely, TNFα seemed to diminish the pool of circulating OPCs by first affecting monocytic precursor cells in bone marrow leading to a subsequently reduced number of monocytes released into blood. This assumption is finally in line with our observations that treatment with etanercept markedly reduced the number of Gr-1 + cells, a mixed myeloid population of neutrophils and Ly6C high monocytes/macrophages in the inflamed joint and that classical Ly6C high monocytes efficiently differentiated into osteoclasts in vitro and were often found in the synovial lining nearby the bone lesions on the tibial joint surface of control treated mice. Although we cannot exclude that etanercept additionally reduced osteoclast-inducing pro-inflammatory cytokine expression in the joint, we could clearly demonstrate a concordant decrease of OPCs of myeloid origin in bone marrow, peripheral blood and in the inflamed synovial tissue upon anti-TNFα treatment of arthritic mice. In light of our observations that adoptively transferred monocytes home equally well to the inflamed joints of etanercept and sham treated mice our data strongly suggest that etanercept reduced monocyte supply from bone marrow rather than monocyte migration into the joint. In accordance with this, TNFα was shown to reduce expression of CXCL12 in the bone marrow, which led to OPC release into the blood [33] . Moreover, our results also nicely correspond to the rapid decline in the number of circulating classical monocytes, the reduced expression of CXC chemokine receptor 4, C-C chemokine receptor type 2 and circulating stromal cell-derived factor-1 observed in patients with RA responding to anti-TNFα treatment with infliximab [34] . However, this could not be observed in our experimental AIA setting. 14 days after arthritis onset treatment with etanercept did not change the levels of circulating chemokines. Either this time period of ongoing arthritis was still too short to find any significant regulation of chemokines that could explain the downregulation of the number of circulating classical monocytes and neutrophils or the reduced peripheral cell numbers did merely reflect the failing supply from bone marrow.
The missed chemokine regulation upon etanercept treatment also makes it less probable that altered proinflammatory cytokine profile was responsible for reduced numbers of circulating classical monocytes and neutrophils, although we cannot exclude that anti-TNFα treatment might have affected immune cells in lymph nodes such as Th17 cells that are associated with neutrophil accumulation and chemokine receptor expression.
Overall, the current study demonstrates that the bone protective effect mediated by blocking TNFα does not seem to mainly depend on direct inhibition of the synovial inflammation in the arthritic joint but may rather rely on limiting OPC supply from the bone marrow, thus limiting the number of monocytes circulating in the blood and able to migrate into the arthritic joint.
Limitations
Our study had several limitations. First, our experimental approach did not allow to directly correlate OPC numbers in different compartments with the synovial osteoclastogenesis. Second, the number of experiments showing the reduction of proliferating bone marrow monocyte precursors was relatively low to draw definite conclusions. Third, we did not correlate the number of osteoclastogenic cells in the synovial compartment with alterations of synovial inflammatory cytokine milieu upon anti-TNFα treatment that could have influenced directed cellular influx although synovial inflammation was still ongoing despite reduced synovial osteoclastogenesis and reduced bone destruction. Fourth, we did not discern if AIA treatment with etanercept did affect immune cells in local lymph nodes such as Th17 which might be associated with neutrophil accumulation and chemokine receptor expression.
Conclusion
Although being largely descriptive, our findings indicate that anti-TNFα treatment with etanercept had a bone protective effect in AIA of the mouse. This effect was not merely a consequence of downregulation of the inflammatory synovial response but coincided with the simultaneous reduction of numbers of osteoclast precursor cells in bone marrow, blood and synovial tissue and therefore suggested a reduced supply from the bone marrow. Our data point to the necessity of subsequent studies using cell tracking approaches to follow up the fate of bone marrow and blood OPCs over the entire course of arthritis [35] .
Supplementary data to this article can be found online at https://doi. org/10.1016/j.bone.2017.10.020.
